Maintain Your Brain

CHeBA Research Project - Maintain Your Brain
Project Members: 
image - Prof Henry Brodaty
Scientia Professor
Ph 02 9385 2585 for research, teaching and academic or 02 9382 3759 for clinical matters
Project Main Description: 

Maintain Your Brain is a randomised controlled trial (ACTRN 12618000851268) of a personalised, multi-modal intervention designed to target modifiable risk factors for dementia in general and AD in particular. Risk factors to be addressed are physical inactivity, poor diet, cognitive inactivity, depression/anxiety and chronic diseases and habits (alcohol, smoking) linked to dementia risk. Up to four intervention modules (physical activity, nutrition, brain training, and peace of mind) will be administered based on individual risk profiles. All activities and assessments will be conducted on a computer with internet access via the Maintain Your Brain digital platform.

Maintain Your Brain will invite over 8,000 individuals through the 45 and Up Study to participate in the trial. These participants will be aged 55-77 years and will not be diagnosed with dementia, Parkinson's disease or multiple sclerosis. Maintain Your Brain will run for 3 years with annual assessments measuring risk factors and cognition.

If you are a participant or if you would like more information, please visit the Maintain Your Brain website.


T +61 (2) 9385 2617

  • Determine the efficacy of a multi-modal targeted intervention delivered on the internet to reduce the rate of cognitive decline in non-demented community-dwelling persons aged 55-77 years and in the long-term to delay the onset of dementia.
  • Examine the cost-effectiveness of the program with a view to making this a national and potentially a globally suitable program.


Dementia affects approximately 44 million people worldwide and by 2050, as the population ages, the prevalence of dementia is set to triple. Globally, it is a leading cause of disability with costs estimated to be more than 800 billion dollars and over the next forty years, these costs are projected to exceed those of all other chronic diseases.

Alzheimer's disease (AD) is the major cause of dementia accounting for over 50% of cases. Available medicines reduce symptom progression but do not alter progression of the disease. In the absence of available disease-modifying drugs, a shift toward delaying onset and possible prevention of AD has gained momentum. Modifiable risk factors account for up to a third of all AD cases.

As dementia is primarily a disease of late-life, delaying the onset by targeting these modifiable risk factors can have a major impact on AD rates. Postponing onset by even two years could reduce AD prevalence by up to 20% and a 5-year delay could potentially halve AD prevalence. Interventions geared at reducing modifiable risk factors would result in significant impacts on worldwide prevalence.


  • Validation of outcomes measures study and pilot study completed. Main trial to commence June 2018.

Other Investigators:

  • Professor Gavin Andrews (UNSW)
  • Professor Kaarin Anstey (UNSW)
  • Professor Nicola Lautenschlager (Melbourne University)
  • Professor Louisa Jorm (UNSW)
  • Professor John McNeill (Monash University)
  • Professor Anthony Maeder (Western Sydney University)
  • Professor Maria Fiatarone Singh (University of Sydney)
  • Professor Michael Valenzuela (University of Sydney)



NHMRC Dementia Team Research Grant.

Project Status: 
Back to Top